Bulletin of the World Health Organization

Compulsory patent licensing and local drug manufacturing capacity in Africa

Olasupo Ayodeji Owoeye

Volume 92, Number 3, March 2014, 214-219

Table 1. Select World Trade Organization (WTO) measures taken in response to the TRIPS Agreementa

Measure Purpose
Least-Developed Country Members – Obligations Under Article 70.9 of the TRIPS Agreement with Respect To Pharmaceutical Products6 Allows least developed countries to refuse to maintain the standards imposed by TRIPS in respect of pharmaceutical products until 1 January 2016 with an option for possible extension
Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health7 Enables countries to produce and export medicines pursuant to a compulsory licence to countries that cannot produce them locally
Amendment of the TRIPS Agreement8 Incorporates provisions of the Implementation Decision as an amendment to the TRIPS Agreement; enters into force once accepted by two thirds of all WTO members
Extension of the Transition Period Under Article 66.1 for Least Developed Country Members9 Extends the time for least developed countries to implement the minimum standard of intellectual property protection required by the TRIPS Agreement to 1 July 2021

a Agreement on Trade-Related Aspects of Intellectual Property Rights.